跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Treg depletion
首页
药物
Treg depletion
Treg depletion
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US 11879014 B2
申请人: TUSK THERAPEUTICS LTD
优先权: 2017
CN
EP
US
WO
5 件公开
ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION
US 2023265200 A1
申请人: CANCER RESEARCH TECH LTD
优先权: 2016
CN
US
2 件公开
COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING A FAS AXIS ANTAGONIST AND A T-REG CELL DEPLETING AGENT ANTAGONIST
US 20250257141 A1
申请人: HOFFMANN LA ROCHE
优先权: 2022
CN
US
2 件公开
IDENTIFICATION OF HIGHLY IMMUNOSUPRESIVE TREG POPULATION IN TUMOR MICROENVIRONMENTS
US 20260069694 A1
申请人: UNIV COLUMBIA
优先权: 2023
US
WO
2 件公开
Method for the identification and separation of non-regulatory T-cells from a mixture of regulatory T-cells
US 9523076 B2
申请人: SCHÖNBRUNN ANNE
优先权: 2009
US
2 件公开
IN VITRO METHOD FOR MODIFYING THE DEPLETION PROFILE OF TREG CELLS PRESENT IN A TOTAL SPLENOCYTE POPULATION OF A BIOLOGICAL SAMPLE BY MEANS OF THE ISOLATION, CULTURING AND EXPOSURE THEREOF TO AN ATP AND POLYMIXIN B MEDIUM
US 2014371159 A1
申请人: UNIV SANTIAGO CHILE
优先权: 2011
US
COMPOUNDS AND METHODS FOR TUMOUR-SPECIFIC CELL DEPLETION
CN 111094346 A
申请人: TUSK THERAPEUTICS LTD
优先权: 2017
CN
Novel antibodies and nucleotide sequences and uses thereof
CN 119161482 A
申请人: BIOINVENT INT AB
优先权: 2018
CN
Compositions and methods for subcutaneous administration of cancer immunotherapy
CN 114555126 A
申请人: OCMEX PHARMACEUTICAL ERLANAN CO LTD
优先权: 2019
CN
Novel anti-ITGB8 antibodies and uses thereof
CN 120225559 A
申请人: INST NAT SANTE RECH MED
优先权: 2022
CN
第 1 / 2 页
上一页
下一页
药物
反馈